"The preliminary data from South Africa suggest a higher risk of reinfection by the variant of the coronavirusomic, but more data is needed to draw firmer conclusions," said Tedros ADHANOM GHEBRAYESUS, from WHO. "There are also indications that suggest that omicron causes less serious symptoms than delta [the most extended variant today], but it is still too early to be sure," he added.
Omicron seems to have a higher reinfection rate but provover milder symptoms, has affirmed the World Health Organization (WHO), as Pfizer and Biontech assured that their VACCO-19 vaccine is "effective" against that variant at the end of three doses.
"The preliminary data in South Africa suggest an increased risk of reinfection by omicron, but more data is needed to draw firmer conclusions," said Tedros Adhanom Ghebreysus, in a meeting with the press in Geneva.
"There are also indications that suggest that omicron causes less serious symptoms than delta [the most widespread variant at present], but it is still too early to be sure," he added.
The Pfizer and Biontech laboratories, on the other hand, insisted on the effectiveness of their current vaccine against the omicron variant.
These ads were preceded by those of High Range scientists of WHO and the White House, which aim that existing anticovid vaccines a priori remain pertinent against omicron, whose recent discovery in South Africa generated a wave of panic.
Date Of Update: 09 December 2021, 00:49
